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Abstracts / Pediatric Hematology Oncology Journal 1 (2016) S1eS33 S13patients with T-ALL developed a CNS relapse, of which one had CNS leu-
kemia at diagnosis and the other eventually developed a combined bone
marrow and CNS relapse.
Conclusion: In conclusion, pCRT can be avoided in most children with ALL
including those with T-cell immunophenotype. Our results demonstrate
an excellent CNS control of leukemia just by using IT performed by strict
adherence to recommended protocols.LM-1_V1.19
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Background: Leukemia & lymphoma together cause 41% of childhood
malignancies .Acute lymphoblastic leukemia (ALL) accounts for 80% of
childhood leukemia, lymphoblastic lymphoma (LL) accounts for nearly
30% of pediatric lymphomas .
The treatment of both is similar and depends on a handful of drugs with a
high toxicity proﬁle.
Current treatment outcomes have improved due to risk stratiﬁcation and
treatment intensiﬁcation. Intensiﬁed chemotherapy targets systemic dis-
ease, as well as tumor cells from the sanctuary sites especially the CNS. This
entails usage of intrathecal therapy and high dose systemic chemotherapy.
This has also increased the incidence and severity of CNS complications .
Around 10-20% of children develop acute neurotoxicity while receiving
treatment for ALL .Others report MRI abnormalities in nearly 20% children
on chemotherapy for ALL, indicating that neurological complications
might be under diagnosed.
The commonly reported acute CNS complications include stroke, posterior
reversible encephalopathy syndrome, peripheral neuropathy, meningitis
and cerebral sinus venous thrombosis (CSVT) .Long term neuroendocrine
and neurocognitive decline cause substantial morbidity.
Discrimination of CNS complications secondary to infection, drug toxicity
or disease per se is perplexing yet essential as treatment in each case is
diametrically opposite. Neuroimaging forms an important tool in reaching
a diagnosis. Management is often shrouded in doubt as no clear guidelines
exist regarding reduction, delay or termination of further chemotherapy.
Methods:
Objective: To analyze the clinical and neuroradiological features of acute
neurotoxicity in children diagnosed with ALL /LL and treated under the
ICICLE protocol.
Study type: Retrospective analysis
Study period: 1 December 2013 to 30 June 2015
Study place: Single pediatric tertiary care centre, North India
Study population:
- 77 consecutive children aged <17 years with ALL/LL whowere eligible for
and treated under the ICICLE protocol.
- Diagnosis of ALL and LL was based on morphological, cytochemical,
immunophenotypic and cytogenetic characteristics of bone marrow as-
pirates and lymph node biopsy respectively.
- All children with neurological complications during treatment were
included.
- Based on clinical ﬁndings, further lumbar puncture, metabolic exami-
nation, CT scan and MRI were done.
Results
- Seven out of 77 children (9%) developed CNS complications during
therapy. None of these 7 children had any baseline neurological disease or
malignant CNS involvement. Summary is shown in table 1 and 2.
- Five of these children showed gradual improvement of which four are still
on chemotherapy while one withdrew from treatment. The remaining two
succumbed to their CNS complications (PRES and hypothalamic syndrome).
Conclusion: Intensiﬁed chemotherapy has improved survival rates for
ALL/LL patients, but also the incidence and severity of CNS complications.
Prompt diagnosis and treatment is essential to prevent mortality and limit
long term disabilityLM-1_V1.20
CYCLIN DEPENDANT KINASE INHIBITOR 2A/B AND IKZF-1 GENE
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Background: Cyclin dependant Kinase Inhibitorand IKZF-1 genes are
tumour suppressor genes implicated in many leukemia though its role in
acute lymphoblastic leukemia has not been studied much. CDKN2A/B are
the cell cycle inhibitor genes while IKZF1 is an important gene lymphoid
development and differentiation.
Design and Methods: 104 pediatric acute lymphoblastic leukemia pa-
tients were investigated for deletion of CDKN2A/2B genes and related
Cytogenetic prognostic factors. CDKN2A/2B and IKZF1 deletions were
investigated by MLPA SALSA kit 0335.
Results: CDKN2A/B deletions were seen in 19.7% of B- lineage ALL and
38.4% of T lineage ALL. 59% were bi allelic deletions. Monoallelic deletions
were found in 50% of B- lineage while all the T-lineage ALL were found to
be bi allelic deletions for both CDKN2a and CDKN2B genes.
Interpretation and conclusions: CDKN2A deletions in T-ALL were seen
to be associated with higher risk group and poor prognostic outcome in T-
ALL. IKZF-1 deletions were seen in 10.9% of B-ALL while no IKZF1 deletions
were not seen in any of the T-ALL cases.
There was no difference in the age group while CDKN2A deletions were
found to be commoner in high risk group and high leukocyte count.
Analysis on survival outcome were also done. IKZF1 gene deletions were
seen associated with total leukocyte count, integrated cytogenetics and
minimal residual disease.
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Introduction: Minimal residual disease (MRD) has been proven to be the
most important indicator of relapse in BCPALL. Currently, it is widely used to
monitor the treatment effectiveness and MRD -based risk stratiﬁcation.
Hence, the methodology for MRD assessment needs to be fast, highly sen-
sitive and most importantly, affordable & widely applicable. Studies have
shown that ﬂow-cytometry based MRD (FC-MRD) technique cannot reach
beyond the 1 in 104 sensitivity and PCR-based MRDmonitoring technique is
more sensitive. However, PCR based MRD assay is expensive, time
consuming, laborious and has lower applicability. We present a study of the
cost-effective high-sensitivity 10-color single tube FC-MRD assay in BCPALL.
Methods: We studied 130 cases of pediatric (<15 year) BCPALL diagnosed
as per WHO criteria. FC-immunophenotyping was performed on Navios
ﬂow-cytometer using bulk-lysis-and-stain method and data was analyzed
with Kaluza-software. MRD was monitored in 164 bone-marrow (BM)
samples at post-induction (PI, day 29-35), post-consolidation (PC, day-90)
and subsequent follow-up time-points (SFU) using 10-color single tube FC-
MRD assay with an additional 4-color nuclear-dye (SYTO13) tube (Table 1).
Samples with cluster of 20 and 2 leukemia associated phenotypes
(LAIPs) were called MRD-positive. Wherever possible, high number of
events (>1.5 million) were acquired. To evaluate the applicability of assay,
number of LAIPs were determined in diagnostic and MRD samples and
post-induction modulation of antigen-expression was also studied.
Results: We studied 130 pediatric (<15 year) BCPALL cases for FC-MRD
monitoring. High number of events were acquired for MRD-assay with
median-events 2341500 (range, 218000 to 3152800). Of 164, MRD was
positive in 69 (42%) samples with median of 0.135% and range of 0.0006%
to 48.3%. We categorized positive MRD results into samples with MRD
<0.001%, 0.001- <0.01%, 0.01- <0.1%, 0.1- <1.0%, 1.0- <10% and >10% and
they were respectively 2.4%, 7.1%, 34.5%, 27.4%, 14.3%, and 14.3%. Of 164
Abstracts / Pediatric Hematology Oncology Journal 1 (2016) S1eS33S14MRD samples, PI-MRD were 130 (79.3%), PC-MRD were 24 (14.6%) and SFU
were 10 (6.1%). Of 130 PI-MRD, 40% samples were positive with median of
0.21% and range 0.0006% to 48.3%. Of 52 PI-MRD-positive cases, PC-MRD
was performed in 46.2% cases and was positive in 62.5% cases (median,
0.075% & range, 0.007-21.5%). Of 10 SFU samples, MRD was positive in 2
cases. Of 130 diagnostic samples, < 2 LAIPs were seen in only 1% and >6
LAIPS in 2% (median LAIPs, 4 & range, 1-8). Similarly, of 164 MRD samples,
four had <2 LAIP (2.4%) and labelled as “suspicious” and in 69 MRD-pos-
itive samples 2-LAIPS were only 7.1%. Furthermore, in 15 samples with
MRD-positive 0.01% and >1.5 million acquired-events, the results were
compared between time-gated initial 500000-events, 1000000 events and
all events acquired. In these 10 samples, eight samples found to be nega-
tive in initial 500000-events and four in initial 1000000-events (as the
number of MRD-events were < 20) highlighting the importance of
acquisition of >1.5 million cells to increase the sensitivity of FC-MRD assay.
Conclusion: We established a cost-effective 10-color single tube FC-MRD
assay with high sensitivity of 1 in 105 and applicability in >97% MRD
samples. Our study showed that acquisition of events less or equal to 1
million cells can reduce the sensitivity of FC-MRD assay.Table 1
Main-MRD-tube Nuclear-dye-tube
Fluorochrome Antibody Clone Company Antibody Clone Company
BV421 CD123 9F5 BD
BV510 CD20 2H7 BD
FITC CD58 AICD58 BC SYTO13 — INVITROGEN
PE CD86 FUN-1 BD
PE-CF594 CD25 M-A251 BD
PC5.5 CD19 J3-119 BC CD19 J3-119 BC
PC7 CD10 ALB1 BC
APC CD34 581 BD
APC-A700 CD45 J.33 BC CD45 J.33 BC
APC-A750 CD38 LS198-4-3 BCMyeloid Malignancies
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Background: Optimal management of infectious complication is the
biggest challenge in children receiving chemotherapy for acute myeloid
leukemia (AML) especially during the induction phase. Signiﬁcant
improvement in overall survival worldwide has been due to advances in
supportive care. The aim of this study is to assess the changing pattern of
blood stream infections (BSI) during AML induction chemotherapy over
the last decade and to analyse the burden of supportive care in managing
these infections.
Material and Methods: The study is a retrospective analysis of children
undergoing AML induction chemotherapy at our centre from 2002 to 2015.
Results: A total of ﬁfty four children had received induction chemotherapy
as per UK MRC protocol were included in the study. Ninety six episodes of
febrile neutropenia were studied. Fifty septic events were recorded and in
twenty seven such episodes children had to be shifted to paediatric inten-
sive care for either ventilatory or ionotropic support. Blood culture proven
septic episodes were seen in 37% of the children, of which 87% were due to
gram negative organisms. High end antibiotics like colistin / tigecycline
were used in 38% of these children. Neutropenic enterocolitis was the most
common focus of infection in these children. Remissionwas achieved in 85%
of children at end of induction and the mortality rate was 10%.
Between the years 2012 to 2015 the incidence of drug resistant gram
negative sepsis had risen to 87% when compared to 20% during the 2002 to2011 period. Though the mortality rates had remained the same in both
groups, the morbidity due to therapy including the duration of hospital
stay, the need for paediatric intensive care support, the use of colistin for
carbapenam resistant infections and the use of granulocyte transfusions to
help tide over the sepsis had dramatically increased.
Conclusion: Western data has shown a rising trend in gram positive in-
fections during AML induction. However, our study has shown predomi-
nantly gram negative infections. The last 5 years has shown a clear increase
in carbapenam resistant Klebsiella infections. This has increased the cost of
therapy signiﬁcantly. Several interventions have been introduced at our
unit to reduce the incidence and mortality due to drug resistant gram
negative sepsis. An active infection control policy with strict surface
cleaning, education of personnel on hand hygiene and restricting unnec-
essary use of high end antibiotics had been the ﬁrst measure. Surveillance
of children for Carbapenem resistance (Carba-R) organisms at the start of
induction therapy has helped identify children at risk. Early introduction of
colistin in Carba-R positive children during febrile neutropenic episodes
has been the main intervention to reduce mortality. The introduction of
neutropenic diet which is lactose and gluten free during the mucositisphase has helped reduce translocation of intestinal bacteria. Early use of
granulocytes in the ﬁrst 48 hours of onset of septic shock has helped as a
bridge till neutrophil recovery.
These measures have kept the mortality rates constant at 10% over the last
decade. However, it comes with a signiﬁcant increase in the cost of sup-
portive care during AML induction.Ă
